Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 12

Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date

Authors Galluzzo M, D'Adamio S, Massaro A, Piccolo A, Bianchi L, Talamonti M

Received 23 October 2018

Accepted for publication 15 February 2019

Published 1 May 2019 Volume 2019:12 Pages 311—321

DOI https://doi.org/10.2147/CCID.S165605

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Jeffrey Weinberg


Video abstract presented by Galluzzo M and D’Adamio S

Views: 449

M Galluzzo,* S D’Adamio,* A Massaro, A Piccolo, L Bianchi, M Talamonti

Dermatology, Department of “Medicina dei Sistemi”, University of Rome Tor Vergata, Rome, Italy
 
*These authors contributed equally to this work

Abstract: The IL-17/IL-23 axis is now understood to influence psoriasis, and the development of novel IL-17 inhibitor medications marks a sea change in the treatment of psoriasis. Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against IL-17RA. This article discusses the mechanism of action and the efficacy and safety profile of brodalumab presented in the literature. Brodalumab, the latest approved anti-IL-17-class medication, is the only one that exerts its effects on IL-17C as well as on IL-17A and IL-17F, blocking the shared IL-17 receptor A. In this sense, considering the recent evidence, brodalumab could have beneficial effects not only on psoriasis, but also on atopic dermatitis. It could also serve as a therapeutic alternative in patients who develop paradoxical eczematous reactions or atopic-like dermatitis during treatment with other anti-IL-17A (secukinumab, ixekizumab).

Keywords: psoriasis, biologics, anti-IL17RA, brodalumab, PASI100, atopic dermatitis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]